Episode 141.0 – Journal Update
11:17 Share

     [
        ](https://coreem.net/podcast/episode-141-0/)         )
  
  
  
     

This week we discuss some recent publications relevant to EM: ADRENAL, Idarucizumab and Time to Furosemide.

        [https://media.blubrry.com/coreem/content.blubrry.com/coreem/Podcast_Episode_141_0_Final_Cut.m4a](https://media.blubrry.com/coreem/content.blubrry.com/coreem/Podcast_Episode_141_0_Final_Cut.m4a))         
  
  
				
		 Download)
	
			
		 [Leave a Comment](https://coreem.net/podcast/episode-141-0/#comments))
	

  		
									
				
				Tags: [ADRENAL](https://coreem.net/tag/adrenal/)), [CHF](https://coreem.net/tag/chf/)), [Corticosteroids](https://coreem.net/tag/corticosteroids/)), [Furosemide](https://coreem.net/tag/furosemide/)), [Idarucizumab](https://coreem.net/tag/idarucizumab/)), [Journal Club](https://coreem.net/tag/journal-club/)), [Journal Update](https://coreem.net/tag/journal-update/)), [Sepsis](https://coreem.net/tag/sepsis/))				
				



  
              ## Show Notes

     **Read More**

Core EM: Idarucizumab for Reversal of Dabigitran)

Core EM: Idarucizumab for Reversal of Dabigitran II)

First10EM: Idarucizumab: Plenty of Optimism, Not Enough Science)

EM Lit of Note: The Door-to-Lasix Quality Measure)

EMS MED: When It’s More Complicated Than A Tweet: Door-To-Furosemide And EMS)

REBEL EM: Door to Furosemide (D2F) in Acute CHF . . . Really?)

emDocs.net): Furosemide in the Treatment of Acute Pulmonary Edema)

Core EM: Door-to-Furosemide Time)

References

Pollack et al. Idarucizumab for dabigitran reversal – full cohort analysis. NEJM 2017; 377(5): 431-41. PMID: 28693366)

Matsue Y et al. Time-to-Furosemide Treatment and Mortality in Patients Hospitalized with Acute Heart Failure J Am Coll Cardiol 2017; 69(25): 3042-51. PMID: 28641794)

Read More)